|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | A61K 31/00 | (2006.01) |
| A61K 31/4166 | (2006.01) | ||
| A61K 31/4439 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 3305285 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17187458.9 |
| Date of filing the European patent application | 2013-09-23 | |
| (97) | Date of publication of the European application | 2018-04-11 |
| (45) | Date of publication and mention of the grant of the patent | 2020-09-02 |
| (46) | Date of publication of the claims translation | 2020-12-10 |
| (30) | Number | Date | Country code |
| 201261705900 P | 2012-09-26 | US |
| (72) |
CHEN, Isan, US
|
| (73) |
Aragon Pharmaceuticals, Inc.,
10990 Wilshire Blvd. Suite 300, Los Angeles, CA 90024,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Anti-androgenai, skirti gydyti nametastazavusį kastracijai atsparų prostatos vėžį |
| ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER |
| Payment date | Validity (years) | Amount | |
| 2023-09-08 | 12 | 289.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2024-08-14 |